High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes
Tóm tắt
High fat diet (HFD) increases the likelihood of dyslipidemia, which can be a serious risk factor for atherosclerosis, diabetes or hepatosteatosis. Although changes in different blood lipid levels were broadly investigated, such alterations in the liver tissue have not been studied before. The aim of the current study was to investigate the effect of HFD on hepatic triglyceride (TG), diglyceride (DG) and ceramide (CER) levels and on the expression of four key genes involved in lipid homeostasis (Pcsk9, Ldlr, Cd36 and Anxa2) in the liver. In addition, the potential role of PCSK9 in the observed changes was further investigated by using PCSK9 deficient mice.
We used two in vivo models: mice kept on HFD for 20 weeks and PCSK9−/− mice. The amount of the major TGs, DGs and CERs was measured by using HPLC–MS/MS analysis. The expression profiles of four lipid related genes, namely Pcsk9, Ldlr, Cd36 and Anxa2 were assessed. Co-localization studies were performed by confocal microscopy. In HFD mice, hepatic PCSK9 expression was decreased and ANXA2 expression was increased both on mRNA and protein levels, and the amount of LDLR and CD36 receptor proteins was increased. While LDLR protein level was also elevated in the livers of PCSK9−/− mice, there was no significant change in the expression of ANXA2 and CD36 in these animals. HFD induced a significant elevation in the hepatic levels of all measured TG and DG but not of CER types, and increased the proportion of monounsaturated vs. saturated TGs and DGs. Similar changes were detected in the hepatic lipid profiles of HFD and PCSK9−/− mice. Co-localization of PCSK9 with LDLR, CD36 and ANXA2 was verified in HepG2 cells. Our results show that obesogenic HFD downregulates PCSK9 expression in the liver and causes alterations in the hepatic lipid accumulation, which resemble those observed in PCSK9 deficiency. These findings suggest that PCSK9-mediated modulation of LDLR and CD36 expression might contribute to the HFD-induced changes in lipid homeostasis.
Tài liệu tham khảo
Csonka C, Baranyai T, Tiszlavicz L, et al. Isolated hypercholesterolemia leads to steatosis in the liver without affecting the pancreas. Lipids Health Dis. 2017. https://doi.org/10.1186/s12944-017-0537-z.
Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J Gastroenterol. 2004. https://doi.org/10.3748/wjg.v10.i21.3081.
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021. https://doi.org/10.1038/s41569-021-00541-4.
World Health Organization. Mortality and global health estimates. The top 10 causes of death. 2019. Available in: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Begg MJ, Sturrock ED, van der Westhuyzen DR. Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters. Eur J Biochem. 2004. https://doi.org/10.1046/j.1432-1033.2003.03953.x.
Mayne J, Ooi TC, et al. Associations between soluble LDLR and lipoproteins in a white cohort and the effect of PCSK9 loss-of-function. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00777.
Bjune K, Wierød L, Naderi S. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-34237-6.
Krone W, Naegele H, Behnke B, Greten H. Opposite effects of insulin and catecholamines on LDL-receptor activity in human mononuclear leukocytes. Diabetes. 1988. https://doi.org/10.2337/diab.37.10.1386.
Windler EET, Kovanen PT, et al. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem. 1980. https://doi.org/10.1016/S0021-9258(19)70487-6.
Streicher R, Kotzka J, et al. SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J Biol Chem. 1996. https://doi.org/10.1074/jbc.271.12.7128.
Kwon HJ, Lagace TA, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA. 2008. https://doi.org/10.1073/pnas.0712064105.
Abifadel M, Varret M, Rabès J, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. https://doi.org/10.1038/ng1161.
Cohen J, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005. https://doi.org/10.1038/ng1509.
Osteikoetxea X, Silva A, et al. Engineered Cas9 extracellular vesicles as a novel gene editing tool. J Extracell Vesicles. 2022. https://doi.org/10.1002/jev2.12225.
Zhang P. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med. 2017. https://doi.org/10.3892/etm.2017.4055.
Demers A, Samami S, Lauzier B, et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015. https://doi.org/10.1161/ATVBAHA.115.306032.
Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014. https://doi.org/10.1146/annurev-nutr-071812-161220.
Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008. https://doi.org/10.1152/ajpgi.00074.2008.
Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9- binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008. https://doi.org/10.1074/jbc.M805971200.
Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocytespecific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008. https://doi.org/10.1002/hep.22354.
Seidah NG, Poirier S, Denis M, et al. Annexin A2 Is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS ONE. 2012. https://doi.org/10.1371/journal.pone.0041865.
Cheung O, Sanyal AJ. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis. 2008. https://doi.org/10.1055/s-0028-1091979.
McClain CJ, Barve S, Deaciuc I. Good fat/bad fat. Hepatology. 2007. https://doi.org/10.1002/hep.21788.
Park TS, Hu Y, Noh HL, et al. Ceramide in cardiotoxin in lipotoxic cardiomyopathy. Lipid Res. 2008. https://doi.org/10.1194/jlr.M800147-JLR200.
Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006. https://doi.org/10.1016/j.plipres.2005.11.002.
Bharath LP, Ruan T, Li Y, et al. Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. Diabetes. 2015. https://doi.org/10.2337/db15-0244.
Kratz M, Cullen P, Kannenberg F, et al. Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. Eur J Clin Nutr. 2002. https://doi.org/10.1038/sj.ejcn.1601288.
Deevska GM, Rozenova KA, Giltiay NV, et al. Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J Biol Chem. 2009. https://doi.org/10.1074/jbc.M807800200.
Ruscica M, Ferri N, Macchi C, et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016. https://doi.org/10.1080/07853890.2016.1188328.
Sarnyai F, Somogyi A, Gór-Nagy Z, et al. Effect of cis- and trans-monounsaturated fatty acids on palmitate toxicity and on palmitate-induced accumulation of ceramides and diglycerides. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21072626.
Hosios AM, Li Z, Lien EC, Heiden MVG. Preparation of lipid-stripped serum for the study of lipid metabolism in cell culture. Bio Protoc. 2018. https://doi.org/10.21769/BioProtoc.2876.
Vukman KV, Ferencz A, et al. An implanted device enables in vivo monitoring of extracellular vesicle-mediated spread of pro-inflammatory mast cell response in mice. J Extracell Vesicles. 2020. https://doi.org/10.1002/jev2.12023.
Xu S, Jay A, Brunaldi K, Huang N, Hamilton JA. CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. Biochemistry. 2013. https://doi.org/10.1021/bi400914c.
Secor JD, Fligor SC, Tsikis ST, Yu LJ, Puder M. Free fatty acid receptors as mediators and therapeutic targets in liver disease. Front Physiol. 2021. https://doi.org/10.3389/fphys.2021.656441.
Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014. https://doi.org/10.1097/MOL.0000000000000114.
Zámbó V, Simon-Szabó L, Szelényi P, et al. Lipotoxicity in the liver. World J Hepatol. 2013. https://doi.org/10.4254/wjh.v5.i10.550.
Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005. https://doi.org/10.1172/JCI23621.
Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA. 2003. https://doi.org/10.1073/pnas.0630588100.
Alamri H, Patterson NH, et al. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis. Anal Bioanal Chem. 2019. https://doi.org/10.1007/s00216-018-1506-8.
Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004. https://doi.org/10.1074/jbc.M313478200.
Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016. https://doi.org/10.1016/j.metabol.2016.02.014.
Nikolova-Karakashian M. Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide. Adv Biol Regul. 2018;70:40–50. https://doi.org/10.1016/j.jbior.2018.11.004.
Kasumov T, Li L, Li M, et al. Ceramide as a mediator of nonalcoholic fatty liver disease and associated atherosclerosis. PLoS ONE. 2015. https://doi.org/10.1371/journal.pone.0126910.
Montefusco DJ, Allegood JC, Spiegel S, Cowart LA. Nonalcoholic fatty liver disease: Insights from sphingolipidomics. Biochem Biophys Res Commun. 2018. https://doi.org/10.1016/j.bbrc.2018.05.078.
Janice M, Teik CO, Lioudmila T, et al. Associations between soluble LDLR and lipoproteins in a white cohort and the effect of PCSK9 loss-of-function. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00777.
Yuanyuan Q, Flora T, Mee JK, et al. Phosphatidylinositol-(4,5)-bisphosphate regulates plasma cholesterol through LDL (Low-Density Lipoprotein) receptor lysosomal degradation. Arterioscler Thromb Vasc Biol. 2020. https://doi.org/10.1161/ATVBAHA.120.314033.
Marcelo AN, Miguel ADM, Marcela ASP, et al. Effects of APOE, APOB and LDLR variants on serum lipids and lack of association with xanthelasma in individuals from Southeastern Brazil. Genet Mol Biol. 2009. https://doi.org/10.1590/S1415-47572009005000028.
Vallim T, Salter AM. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2010. https://doi.org/10.1016/j.plefa.2010.02.016.
Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res. 2009. https://doi.org/10.1194/jlr.M800542-JLR200.
Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005. https://doi.org/10.1073/pnas.0501652102.
Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996. https://doi.org/10.1006/abbi.1996.0030.
Koonen DP, Jacobs RL, Febbraio M, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007. https://doi.org/10.2337/db07-0907.
Wilson CG, Tran JL, et al. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology. 2016. https://doi.org/10.1210/en.2015-1866.
Cui CJ, Li S, Li JJ. PCSK9 and its modulation. Clin Chim Acta. 2015. https://doi.org/10.1016/j.cca.2014.10.044.
Xia XD, Peng ZS, Gu HM, et al. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021. https://doi.org/10.3389/fcvm.2021.764038.
Cariou B, Langhi C, Le Bras M, et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab. 2013. https://doi.org/10.1186/1743-7075-10-4.
Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS ONE. 2012;7(7):e41865. https://doi.org/10.1371/journal.pone.0041865.
Amput P, McSweeney C, Palee S, et al. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomed Pharmacother. 2019. https://doi.org/10.1016/j.biopha.2018.10.138.
Rezaei TM, Rezaei TM, Zamanian AM. ANXA2, PRKCE, and OXT are critical differentially genes in Nonalcoholic fatty liver disease. Gastroenterol Hepatol Bed Bench. 2019. https://doi.org/10.22037/ghfbb.v12i2.1563.